SCHEMBL15470656

SCHEMBL15470656

CC(C)(O)Cn1cc(C(C)(C)C)ccc1=O

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.37
NPC1 O15118 2/20 0.37
TP53 P04637 2/20 0.37
RAB9A P51151 2/20 0.37
MITF O75030 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 3/20 0.35
MAPT P10636 3/20 0.35
KDM4E B2RXH2 2/20 0.35
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
LIPC P11150 2/20 0.33
LIPG Q9Y5X9 2/20 0.33
TYR P14679 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16418594 0.86 PTGDR2 (0.40) LMNANPC1TP53RAB9AMITF
SCHEMBL15043720 0.85 LMNA (0.39) LMNANPC1TP53RAB9AMITF
SCHEMBL14407047 0.80 ALDH1A1 (0.56) TP53KMT2AALDH1A1MAPTKDM4E
SCHEMBL15043714 0.79 ALDH1A1 (0.41) LMNANPC1TP53RAB9AMITF
SCHEMBL590179 0.79 KMT2A (0.40) NPC1RAB9AL3MBTL1KMT2AALDH1A1
SCHEMBL15807128 0.77 PTGDR2 (0.35) LMNAL3MBTL1KMT2AALDH1A1MAPT
SCHEMBL16418601 0.77 ALDH1A1 (0.62) LMNANPC1TP53RAB9ASMN1; SMN2
SCHEMBL13239668 0.76 LMNA (0.41) LMNANPC1TP53RAB9AMITF
SCHEMBL16418589 0.76 KDM4E (0.38) LMNANPC1TP53RAB9AMITF
SCHEMBL14407050 0.76 KDM4E (0.38) LMNANPC1TP53RAB9AMITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096527-B2 TRPM8 antagonists and their use in treatments AMGEN INC. (US) 2015-08-04 US disclosed
US-8987314-B2 Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2015-03-24 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045811-A1 AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 LMNA 710/4885NPC1 702/4885TP53 4199/4885
US-20140045811-A1 AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, LIPE, CEL LMNA 1733/4885NPC1 1652/4885TP53 3676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.